

---

## **A D H O C   A N N O U N C E M E N T**

---

### **STRATEC Reports Successful Completion of Equity Placement**

Birkenfeld, September 27, 2005

STRATEC Biomedical Systems AG has placed 329,989 shares from a capital increase to the exclusion of the shareholders' subscription rights within the framework of a private placement among institutional investors at Euro 37,00 per share. The company raised gross proceeds of around Euro 12.2 million.

In a parallel placement, 263,992 shares from the holdings of the founder's family were placed with institutional investors at the same price.

WestLB AG accompanied the transaction as sole lead manager.

The proceeds from the capital increase are to be used to capitalize on existing and future expansion opportunities. In particular, the proceeds are to be channeled into the financing of existing and future development partnerships, as well as into the further development of the proven platform concept on which two of STRATEC's most successful families of analyzer systems are based. Moreover, this measure is intended to serve to access further growth markets and to strengthen the company's liquidity base.

As a result of the capital increase, the number of shares in the company issued has increased from 3,330,150 to 3,660,139.

To ensure a timely delivery of shares to new investors, WestLB AG has entered into share loan agreements with members of the founder's family.

On account of the capital increase and the placement of shares from the holdings of the founder's family, the company's free float has shown an overall increase from 43% to 56%.

### **Information and explanatory remarks concerning this ad hoc announcement:**

This announcement is not being issued in the United States of America and should not be distributed to persons in the United States or to publications with a general circulation in the United States.

This announcement does not constitute an offer of securities for sale in the United States, neither does it represent a request for the submission of bids for the purchase of securities in the United States.

The securities offered have not been and are not intended to be registered under the U.S. Securities Act of 1933, and may not be offered for sale or sold in the United States in the absence of such registration unless a corresponding exemption has been obtained.

Moreover, this announcement does not constitute an offer of securities for sale or a request for the submission of bids for the purchase of securities in such countries or jurisdictions where the respective legal provisions governing the trading of securities do not permit such offer for sale or request for the submission of bids for the purchase of securities, or the sale of securities, without prior registration or approval.

### **About STRATEC**

STRATEC Biomedical Systems AG (<http://www.stratec-biomedical.de>) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges.

The STRATEC group comprises the listed holding company "STRATEC Biomedical Systems AG" as well as the wholly owned subsidiaries "STRATEC NewGen GmbH" and "Robion AG".

**Further information can be obtained from:**

STRATEC Biomedical Systems AG

Investor Relations

André Loy

Gewerbestr. 37

75217 Birkenfeld

Germany

Tel: +49 (0)7082 7916-190

Fax: +49 (0)7082 7916-999

E-Mail: [ir@stratec-biomedical.de](mailto:ir@stratec-biomedical.de)